PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist approved in the US as Vyleesi. Most searches for PT 141 benefits mix marketing claims with a genuinely unusual fact: PT-141 (bremelanotide) is one of the few peptides in this category that reached FDA approval for a defined human indication. It works through the brain rather than the bloodstream, and its studied benefits are narrower and better documented than the supplement pages suggest.

New here? Start with the overview of peptides studied for sexual desire to see where bremelanotide sits among the alternatives.

What PT-141 (bremelanotide) actually is

PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide derived from the melanocyte-stimulating hormone family. It is a metabolite of an earlier compound, Melanotan II, redesigned to act on sexual-response pathways rather than skin pigmentation.

Unlike PDE5 drugs such as sildenafil, which act on blood flow, bremelanotide acts on the central nervous system. It is an agonist at the melanocortin receptors, with MC4R signaling in the hypothalamus considered the most relevant to arousal [1][3].

Attribute	Detail
Compound class	Melanocortin receptor agonist (cyclic heptapeptide)
Most studied for	Hypoactive sexual desire disorder (HSDD) in premenopausal women
Evidence tier	Human (phase 3 RCT) for HSDD; human pilot for male ED
Legal / regulatory status (US)	FDA-approved as Vyleesi (women); not approved for men; research versions sold “for research use only”

How PT-141 works: the melanocortin mechanism

The mechanism is what makes PT-141 different from every other compound in the sexual-health conversation. It does not dilate vessels or raise testosterone. It binds melanocortin receptors in the brain, and MC4R activation in hypothalamic and limbic regions is linked to sexual arousal signaling [3].

Because the pathway is central, the effect is described as increasing desire, not just enabling a physical response. Bremelanotide activates MC4R in the central nervous system, which distinguishes it from peripheral erectile-dysfunction drugs (Evidence tier: Human / Regulatory) [1][3].

That central action also explains its known side effects. Melanocortin receptors sit in pathways that affect nausea, flushing, and blood pressure, which is why those were the most common adverse events reported in trials [1].

PT-141 benefits supported by human research

Here the evidence splits cleanly by population. The strongest data is in women; the male data is older and preliminary.

Benefit in premenopausal women (HSDD)

The two phase 3 RECONNECT trials randomized roughly 1,247 premenopausal women with HSDD to bremelanotide or placebo over 24 weeks. Bremelanotide significantly improved sexual desire and reduced related distress versus placebo (Evidence tier: Human, phase 3 RCT) [1].

The size of the effect was real but modest. Integrated results showed an increase in the desire score (FSFI-D) of about 0.35 and a reduction in the distress score (FSDS-DAO) of about 0.33, both statistically significant [1]. This is the evidence base that supported FDA approval of Vyleesi in 2019.

Honest framing matters. PT-141 raised desire scores modestly, not dramatically, and long-term follow-up focused on safety and tolerability rather than large jumps in outcome [2].

Benefit in men (erectile response)

The male research is where marketing outruns the science. An early double-blind study of intranasal PT-141 reported a statistically significant erectile response in men with mild-to-moderate erectile dysfunction, with onset around 30 minutes (Evidence tier: Human pilot) [4].

That work is real but early-phase and small, and later development for male ED did not produce an approved product on its own. PT-141 is not FDA-approved for men (Evidence tier: Regulatory), so any male use is off-label or research-stage [4].

Evidence and legal status at a glance

Studied use	Mechanism	Evidence maturity	Regulatory status (US)
Low sexual desire, premenopausal women	MC4R activation in CNS	Human, phase 3 RCT [1]	FDA-approved as Vyleesi
Erectile dysfunction, men	Central melanocortin signaling	Human pilot / early phase [4]	Not FDA-approved (off-label)
General libido / “arousal” claims	Same central pathway	Extrapolated, not directly proven	Not approved for this use

Key takeaways

• PT-141 (bremelanotide) is a melanocortin receptor agonist, acting on MC4R in the brain rather than on blood flow like sildenafil [3].
• The strongest PT-141 benefit is in premenopausal women with HSDD, where phase 3 RECONNECT trials showed modest, significant gains in desire [1].
• The women’s-health effect size was small (FSFI-D change near 0.35), so bremelanotide is a real but limited option, not a dramatic fix [1].
• Male erectile-response data exists but is early-phase, and PT-141 is not FDA-approved for men [4].
• Vyleesi is a regulated prescription product, while research-labeled PT-141 is sold “for research use only” and is legally distinct.

Frequently asked questions

What are the main PT-141 benefits?

The best-documented PT-141 benefit is a modest, statistically significant increase in sexual desire and lower distress in premenopausal women with HSDD, shown in phase 3 trials [1]. Early studies also reported erectile response in men, but that use is not approved.

Is PT-141 FDA-approved?

Partly. Bremelanotide is FDA-approved as Vyleesi for premenopausal women with acquired, generalized HSDD [1]. It is not approved for men or for general libido enhancement.

How does PT-141 work?

It is a melanocortin receptor agonist that activates MC4R in the central nervous system, a pathway linked to sexual arousal [3]. This is different from erectile-dysfunction drugs that act on blood flow.

Does PT-141 work for men?

An early double-blind study reported a significant erectile response in men with mild-to-moderate ED [4]. The data is preliminary, and PT-141 has no FDA approval for male use.

What are the reported side effects?

In trials the most common adverse events were nausea, flushing, and headache, occurring in 10 percent or more of participants [1]. Melanocortin receptors also influence blood pressure, which is monitored in the approved product.

Is research-grade PT-141 the same as Vyleesi?

No. Vyleesi is a regulated prescription drug with a specific indication, while research-labeled bremelanotide is sold “for research use only” and is not a substitute for an approved medicine.

Interest in PT-141 benefits sits where melanocortin pharmacology meets sexual medicine: bremelanotide, the cyclic heptapeptide and MC4R agonist derived from Melanotan II, is the active ingredient in Vyleesi, the first melanocortin drug FDA-approved for hypoactive sexual desire disorder, while the intranasal erectile-dysfunction studies in men and the RECONNECT phase 3 trials in premenopausal women mark the two poles of its evidence base, and Compound Universe Genome tracks each of these against the primary literature so the picture reflects evidence maturity rather than supplement marketing.

To keep the framing honest: the documented PT 141 benefits are a modest, evidence-backed improvement in sexual desire for premenopausal women with HSDD, plus early, unapproved erectile-response findings in men. It is one of the rare peptides with real regulatory standing, but that standing is narrow, and everything outside the approved women’s-health indication remains research-stage. For the wider context, see the bremelanotide (PT-141) profile or the Compound Universe Genome peptide legality guide.

References

1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. PMID 31599840 / DOI 10.1097/AOG.0000000000003500.
2. Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. PMC6819023.
3. Bremelanotide for Treatment of Female Hypoactive Sexual Desire (review of melanocortin MC4R mechanism). PMC8788464.
4. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID 14963471.